SubscribeSign In
LeaderPortfolio
Billionaire Profile
Park Soon-jae
Global Rank
#1625

Image: 뉴스인스타 | CC BY 3.0 | via Wikimedia Commons

Park Soon-jae

CEO, Biopharmaceuticals
SOUTH KOREA
Real-Time Net Worth
$2.592B
Estimated based on Biopharmaceuticals stock value as of April 21, 2026
+1.5% (24h)
Age
71
Source
Biopharmaceuticals
Industry
Healthcare
Citizenship
SOUTH KOREA

Biography

Park Soon-jae is a South Korean businessman and biochemist, currently the CEO and former chairman of Alteogen, a biotechnology company specializing in biosimilars and biobetters. Born on December 22, 1954, Park has a net worth estimated at $2.28 billion as of March 2026. His wealth stems primarily from his ventures in the biopharmaceutical industry. Park founded Alteogen in 2008 with his wife, Chung Hye-shin, and has led the company's growth, focusing on innovative drug development, including the ALT-B4 technology, an enzyme that allows drugs to be administered subcutaneously instead of intravenously. Prior to Alteogen, Park held leadership roles at LG Life Sciences and Hanwha Petrochemical, and was a postdoctoral researcher at MIT.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/21/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Park Soon-jae was born on December 22, 1954, in Gunsan, South Korea. He graduated from Seoul High School in 1973. He then pursued higher education, earning a bachelor's degree in biochemistry from Yonsei University in 1980. He furthered his studies in the United States, obtaining a PhD in biochemistry from Purdue University in 1985.

Rise to Success

His career began with research experience at the Massachusetts Institute of Technology (MIT) from 1986 to 1988. After returning to South Korea, Park took on various biotechnology research positions. In 1998, he became the head of development at LG Chem. In 2006, he became managing director of Dream Pharma. Park Soon-jae founded Alteogen in 2008. He has a 19.2% stake in Alteogen as of June 2024. In December 2024, Alteogen had the largest market capitalization in the KOSDAQ exchange.

Key Business Strategies

Alteogen's key business strategy revolves around developing biosimilars and biobetters. The company is known for its ALT-B4 enzyme technology that allows drugs to be administered subcutaneously. In 2024, Alteogen announced a licensing deal with Merck to use ALT-B4 for the cancer drug pembrolizumab, which led to a significant increase in the company's share price. In December 2025, Park Soon-jae stepped down as CEO of Alteogen to become the chairman of the board, focusing on long-term vision and strategy.

Philanthropy

Information on Park Soon-jae’s specific philanthropic endeavors is not readily available in the search results.

Career Milestones

1980

Graduated from Yonsei University

Earned a bachelor's degree in biochemistry.

1985

Obtained PhD from Purdue University

Completed a doctorate in biochemistry.

1986-1988

Researcher at MIT

Worked as a researcher at the Massachusetts Institute of Technology.

1998

Head of Development at LG Chem

Took on a leadership role in development at LG Chem.

2006

Managing Director of Dream Pharma

Became managing director of Dream Pharma.

2008

Founded Alteogen

Co-founded the biotechnology company Alteogen.

2010

CEO of Alteogen

Assumed the role of CEO at Alteogen.

2025

Chairman of the Board at Alteogen

Became the chairman of the board at Alteogen.

Philanthropy & Social Impact

Unknown

Not Available

Undisclosed

Philanthropic information not found in the search results.

Compare Park Soon-jae

Net Worth Face-off
Park Soon-jae vs Elon Musk
Compare Wealth →
Net Worth Face-off
Park Soon-jae vs Jeff Bezos
Compare Wealth →
Net Worth Face-off
Park Soon-jae vs Mark Zuckerberg
Compare Wealth →